
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Preclinical Pharmacology |
The Johns Hopkins Oncology Center, Johns Hopkins University, Baltimore, Maryland 21231 [H. A. H., V. R. D., K. A. B., W. L. D., R. A. C., N. E. D.], and Wayne State University, Detroit, Michigan 48202 [P. M. W.]
Polyamines are essential for cell growth and differentiation. Structural
polyamine analogues have been shown to have antitumor activity in
experimental models including breast cancer. The ability of polyamine
analogues to alter activity of cytotoxic chemotherapeutic agents in
breast cancer models has not been evaluated. This study evaluates the
ability of two polyamine analogues,
N1-ethyl-N11-[(cyclopropyl)methyl]-4,8-diazaundecane
(CPENSpm) and
N1-ethyl-N11-[(cycloheptyl)methyl]4,8-diazaundecane
(CHENSpm) to synergize with cytotoxics in five human breast cancer cell
lines. Antagonism, additivity, or synergy of the combinations was
determined using the median effect/combination index model. The
chemotherapeutic agents chosen,
cisdiaminechloroplatinum(II), doxorubicin,
5-fluorouracil, fluorodeoxyuridine, 4-hydroperoxycyclophosphamide,
paclitaxel, docetaxel, and vinorelbine, all have antitumor activity in
breast cancer and represent a spectrum of mechanisms. Three treatment
schedules of polyamine analogue and cytotoxic were tested in MCF-7 and
MDA-MB-468 lines, demonstrating a schedule-dependence of synergistic
growth inhibition. Cytotoxic agent alone for 24 h followed by
polyamine analogue alone for 96 h resulted in the most synergistic
combinations and the greatest synergy. This schedule was then tested in
three additional breast cancer lines, and several synergistic
combinations were again identified. Two cytotoxics, vinorelbine and the
fluoropyrimidines, showed the most promise in combination with the
polyamine analogues. They were able to synergize with one or both
polyamine analogues in most of the breast cancer cell lines. CPENSpm
was also able to synergize with virtually all of the cytotoxics in the
estrogen receptor
-positive MCF-7 and T-47D lines. These preclinical
data demonstrate a treatment schedule and combinations of polyamine
analogues and cytotoxics that will be important to study
mechanistically and clinically for breast cancer.
This article has been cited by other articles:
![]() |
A. Pledgie-Tracy, M. D. Sobolewski, and N. E. Davidson Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines Mol. Cancer Ther., March 1, 2007; 6(3): 1013 - 1021. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. L. Allen, E. G. McLean, J. Boyer, A. McCulla, P. M. Wilson, V. Coyle, D. B. Longley, R. A. Casero Jr., and P. G. Johnston The role of spermidine/spermine N1-acetyltransferase in determining response to chemotherapeutic agents in colorectal cancer cells Mol. Cancer Ther., January 1, 2007; 6(1): 128 - 137. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wang and R. A. Casero Jr. Mammalian Polyamine Catabolism: A Therapeutic Target, a Pathological Problem, or Both? J. Biochem., January 1, 2006; 139(1): 17 - 25. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Pledgie, Y. Huang, A. Hacker, Z. Zhang, P. M. Woster, N. E. Davidson, and R. A. Casero Jr. Spermine Oxidase SMO(PAOh1), Not N1-Acetylpolyamine Oxidase PAO, Is the Primary Source of Cytotoxic H2O2 in Polyamine Analogue-treated Human Breast Cancer Cell Lines J. Biol. Chem., December 2, 2005; 280(48): 39843 - 39851. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Marverti, M. G. Monti, A. E. Pegg, D. E. McCloskey, S. Bettuzzi, A. Ligabue, A. Caporali, D. D'Arca, and M. S. Moruzzi Spermidine/spermine N1-acetyltransferase transient overexpression restores sensitivity of resistant human ovarian cancer cells to N1,N12-bis(ethyl)spermine and to cisplatin Carcinogenesis, October 1, 2005; 26(10): 1677 - 1686. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Huang, J. C. Keen, E. Hager, R. Smith, A. Hacker, B. Frydman, A. L. Valasinas, V. K. Reddy, L. J. Marton, R. A. Casero Jr., et al. Regulation of Polyamine Analogue Cytotoxicity by c-Jun in Human MDA-MB-435 Cancer Cells Mol. Cancer Res., February 1, 2004; 2(2): 81 - 88. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Wolff, D. K. Armstrong, J. H. Fetting, M. K. Carducci, C. D. Riley, J. F. Bender, R. A. Casero Jr., and N. E. Davidson A Phase II Study of the Polyamine Analog N1,N11-Diethylnorspermine (DENSpm) Daily for Five Days Every 21 Days in Patients with Previously Treated Metastatic Breast Cancer Clin. Cancer Res., December 1, 2003; 9(16): 5922 - 5928. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Huang, E. R. Hager, D. L. Phillips, V. R. Dunn, A. Hacker, B. Frydman, J. A. Kink, A. L. Valasinas, V. K. Reddy, L. J. Marton, et al. A Novel Polyamine Analog Inhibits Growth and Induces Apoptosis in Human Breast Cancer Cells Clin. Cancer Res., July 1, 2003; 9(7): 2769 - 2777. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |